Emerging Research

Mazdutide

GLP & Metabolic · ['IBI362', 'LY3305677', 'OXM analog']

Mazdutide is an investigational glucagon-like peptide-1 (GLP-1) receptor and glucagon receptor dual agonist derived from an oxyntomodulin-based scaffold, studied in clinical trials for metabolic endpoints.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.

Molecular Formula

C207H317N45O65

Molecular Weight

4476 g/mol

PubChem

CID 167312357 ↗

Research Level

Emerging Research

Browse the store →

Mazdutide (development codes IBI362 / LY3305677) is an investigational peptide engineered as a dual agonist of the glucagon-like peptide-1 (GLP-1) receptor and the glucagon (GCG) receptor. Its design is based on an oxyntomodulin scaffold, a naturally occurring gut hormone that activates both receptor systems [1].

The molecule has been evaluated in a series of clinical trials, including studies conducted in China, examining metabolic and body-weight related endpoints in adult participants [2]. As an investigational compound, it has not received marketing authorization for general use at the time of writing.

Research interest in mazdutide centers on the concept of combining incretin (GLP-1) and glucagon receptor activity within a single molecule, an approach studied in the broader class of multi-receptor metabolic peptides.

Mazdutide acts as an agonist at two G-protein-coupled receptors. GLP-1 receptor activation is associated in the literature with glucose-dependent insulinotropic signaling and effects on gastric and appetite-related pathways, while glucagon receptor activation is associated with hepatic and energy-expenditure pathways studied in preclinical and clinical settings [1][3].

The dual-agonist design is intended, in the published rationale, to combine the two receptor activities. Reported effects and receptor pharmacology are described here strictly as findings from cited studies and not as outcomes for any individual.

Dual GLP-1 receptor / glucagon receptor pharmacology and receptor-selectivity characterization [1]
Body-weight and metabolic endpoints in randomized clinical trials in adult participants [2]
Glycemic parameters in participants with type 2 diabetes in controlled trials [3]
Effects on hepatic lipid and liver-associated markers studied in the multi-receptor agonist class [1]
Pharmacokinetic and tolerability profiling in phase 1 and phase 2 studies [2]

📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

Phase 2 randomized trial (adults, overweight/obesity): A randomized, double-blind, placebo-controlled trial evaluated mazdutide in adult participants and measured change in body weight and metabolic parameters across dose groups over the study period, reporting dose-related changes versus placebo [2]. Reported here for scientific reference only.

Phase 2 trial (type 2 diabetes): A controlled clinical study in participants with type 2 diabetes assessed change in HbA1c and additional glycemic and metabolic measures across randomized groups, reporting the primary and secondary endpoints defined in the protocol [3].

Preclinical receptor pharmacology: In vitro and animal studies characterized dual GLP-1R/GCGR potency and metabolic effects of the oxyntomodulin-based scaffold, informing the clinical development rationale [1].

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

GLP-1 receptor agonists (e.g., semaglutide)Caution

Overlapping GLP-1 receptor pharmacology is a consideration in comparative research contexts.

Glucagon receptor agonists / dual agonistsCaution

Shared receptor targets relevant to study design and interpretation.

Insulin secretagoguesCaution

Glycemic pathways are studied together in the metabolic literature.

Oxyntomodulin analogsCompatible

Structurally related scaffolds studied in the same class.

What receptors does mazdutide target?

Published studies describe it as a dual agonist at the GLP-1 receptor and the glucagon receptor, based on an oxyntomodulin scaffold [1].

Is mazdutide an approved drug?

It is described in the literature as an investigational compound evaluated in clinical trials; it has not received general marketing authorization at the time of writing [2].

What has clinical research measured?

Trials have reported body-weight, glycemic (HbA1c), and metabolic endpoints in randomized, controlled designs [2][3].

How is it different from single-target GLP-1 agonists?

Its design adds glucagon receptor agonism to GLP-1 activity, a distinction studied in the multi-receptor peptide class [1].

Is this product intended for human use?

No. This material is offered strictly for laboratory research use only. It is not a drug, supplement, or food and is not intended to diagnose, treat, cure, or prevent any disease, nor for human or veterinary use.

Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.